Pharmacology
Original Paper
Effect of Amiodarone on Phospholipid Content and Composition in Heart, Lung, Kidney and Skeletal Muscle: Relationship to Alteration of Thyroid FunctionRabkin S.W.Faculty of Medicine, University of British Columbia, Vancouver, B.C., Canada
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: May 25, 2005
Accepted: August 01, 2005
Published online: February 22, 2006
Issue release date: February 2006
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 6
ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)
For additional information: https://www.karger.com/PHA
Abstract
To investigate the effect of chronic amiodarone treatment on tissue phospholipids, a marker of amiodarone-induced toxicity, and to test the hypothesis that tissue phospholipids changes are related to amiodarone-induced effects on thyroid function, male Wistar rats were treated with amiodarone and tissue phospholipid content and fractions were assessed. Twenty-six animals were allocated to 4 groups: (i) group 1 received amiodarone, 20 mg/kg per day, for 3 weeks (n = 6); (ii) group 2 received amiodarone for 5 weeks (n = 6); (iii) group 3 received drug for 6 weeks (n = 6), and (iv) group 4 (control group) received the diluent for 6 weeks (n = 8). Total phospholipid content of lung, kidney and skeletal muscle but not heart was increased after 3 weeks of amiodarone treatment. With longer durations of treatment, the phospholipid content was significantly (p < 0.05) reduced in all four organs. The proportion of phospholipids in different classes was modified by amiodarone treatment with the most consistent changes across different tissues being reductions in phosphatidylethanolamine and increases in phosphatidylserine. Serum thyroxine concentration was significantly (p < 0.05) reduced at 5 weeks of treatment and thereafter. There was a significant correlation between serum thyroxine and total phospholipid concentration in heart (r = 0.555; p < 0.05) and lung (r = 0.502; p < 0.05). For heart, there was a significant correlation between serum thyroxine and the distribution of phospholipid classes, mainly for phosphatidylserine even after considering amiodarone dose. The same was found in the lung. In the kidney and skeletal muscle, there was a significant (p < 0.05) correlation between serum thyroxine and the proportion of phospholipids in phosphatidylcholine and sphingomyelin. In conclusion, this study presents the novel finding of a biphasic tissue phospholipid response to amiodarone characterized by a short term increase in phospholipids in lung, kidney and skeletal muscle but not the heart followed by a long term decline in phospholipids in all four organs that is likely due to a direct action of amiodarone on phospholipid metabolism and potentially the result of amiodarone-induced reduction in thyroid function.
© 2006 S. Karger AG, Basel
Related Articles:
References
- Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gagne P, Nattel S, Thibault B: Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. New Engl J Med 2000;342:913–920.
- Kudenchuk PJ, Cobb LA, Copass MK, Cummins RO, Doherty AM, Fahrenbruch, CE, Hallstrom AP, Murray WA, Olsufka M, Walsh T: Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 1999;341:871–878.
- Martin WJ 2nd, Rosenow EC 3rd: Amiodarone pulmonary toxicity: recognition and pathogenesis. Part I. Chest 1988;93:1067–1075. Part 2:1242–1248.
- Lewis JH, Mullick F, Ishak KG, Ranard RC, Ragsdale B, Perse RM, Rusnock, EJ, Wolke A, Benjamin SB, Seeff LB, et al: Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol 1990;21:59–67.
- Reasor MJ, Kacew S: An evaluation of possible mechanisms underlying amiodarone-induced pulmonary toxicity. Proc Soc Exp Biol Med 1996;212:297–304.
- Camus P, Jeannin L: Speculation on the mechanism for amiodarone-induced pneumonitis. Radiology1984;150:279–280.
- Agoston M, Orsi F, Feher E, Hagymasi K, Orosz Z, Blazovics A, Feher J, Vereckei A: Silymarin and vitamin E reduce amiodarone-induced lysosomal phospholipidosis in rats. Toxicology 2003;190:231–241.
- Hostetler KY, Reasor MJ, Walker ER, Yazaki PJ, Frazee BW: Role of phospholipase A inhibition in amiodarone pulmonary toxicity in rats. Biochim Biophys Acta 1986;875:400–405.
- Kodavanti UP, Mehendale HM: Amiodarone- and desethylamiodarone-induced pulmonary phospholipidosis, inhibition of phospholipases in vivo, and alteration of [14C]amiodarone uptake by perfused lung. Am J Resp Cell Molec Biol 1991;4:369–378.
- Lullmann H, Lullmann-Rauch R, Wassermann O: Lipidosis induced by amphiphilic cationic drugs. Biochem Pharmacol 1978;27:1103–1108.
- Joshi UM, Kodavanti PR, Coudert B, Dwyer TM, Mehendale HM: Types of interaction of amphiphilic drugs with phospholipid vesicles. J Pharmacol Exp Ther 1988;246:150–157.
- Sirajudeen KN, Gurumoorthy P, Devaraj H, Devaraj SN: Amiodarone-induced phospholipidosis: an in vivo [14C]-acetate uptake study in rat. Drug Chem Toxicol 2002;25:247–254.
- Rabkin SW: Effect of amiodarone and desethylamiodarone on choline uptake and phosphatidylcholine biosynthesis in cultured chick cardiac myocytes. J Mol Cell Cardiol 1990;22:965–974.
- Riva E, Marchi S, Pesenti A, Bizzi A, Cini M, Veneroni E, Tavbani E, Boeri R, Bertani T, Latini R: Amiodarone induced phospholipidosis: biochemical, morphological and functional changes in the lungs of rats chronically treated with amiodarone. Biochem Pharmacol 1987;36:3209–3214.
- Reasor MJ, Ogle CL, Walker ER, Kacew S: Amiodarone-induced phospholipidosis in rat alveolar macrophages. Am Rev Resp Dis 1988;137:510–518.
- Chatelain P, Brotelle R: Phospholipid composition of rat lung after amiodarone treatment. Res Commun Chem Pathol Pharmacol 1985;50:407–418.
- Heath MF, Costa-Jussa FR, Jacobs JM, Jacobson W: The induction of pulmonary phospholipidosis and the inhibition of lysosomal phospholipases by amiodarone. Br J Exp Pathol 1985;66:391–397.
- Shaikh NA, Downar E, Butany J: Amiodarone – an inhibitor of phospholipase activity: a comparative study of the inhibitory effects of amiodarone, chloroquine and chlorpromazine. Mol Cell Biochem 1987;76:163–172.
- Harris L, Kimura Y, Shaikh NA: Phospholipase inhibition and the electrophysiology of acute ischemia: studies with amiodarone. J Mol Cell Cardiol 1993;25:1075–1090.
- Martino E, Bartalena L, Bogazzi F, Braverman LE: The effects of amiodarone on the thyroid. Endocr Rev 2001;22:240–254.
- Klein I, Ojamaa K: Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344:501–509.
- Plomp TA, Wiersinga WM, Maes RA: Tissue distribution of amiodarone and desethylamiodarone in rats after multiple intraperitoneal administration of various amiodarone dosages. Arzneimittel-Forsch1985;35:122–129.
- Tomlinson CW, Godin DV, Rabkin SW:Adriamycin cardiomyopathy: implications of cellular changes in a canine model with mild impairment of left ventricular function. Biochem Pharmacol 1985;34:4033–4041.
- Reed CF, Swisher SN, Marinetti GV, Eneen EG: Studies of the lipids of the erythrocyte. I. Quantitative analysis. J Lab Clin Med 1960;56:281–289.
- Rabkin SW: The effect of chlorpromazine and trifluoperazine on choline metabolism in cardiac myocytes exposed to anoxia. Biochem Pharm 1989;38:2349–2355.
- Anderson RL, Davis S: An organic phosphorus assay which avoids the use of hazardous perchloric acid. Clin Chim Acta 1982;121:111–116.
- Najjar TA: Disposition of amiodarone in rats after single and multiple intra-peritoneal doses. Eur J Drug Metab Pharmacokinet2000;25:199–203.
- Shaikh NA, Downar E: Effects of chronic amiodarone treatment on cat myocardial phospholipid content and on in vitro phospholipid catabolism. Mol Cell Biochem 1987;78:17–25.
-
Shaikh NA: Effect of amiodarone therapy on the time course of myocardial phospholipid hydrolysis during in vitro total ischaemia in cat hearts. J Mol Cell Cardiol 1992, pp 7–21.
- Brennan FJ, Brien JF, Armstrong PW: Plasma concentration time course and pharmacological effects of a standardized oral amiodarone dosing regimen in humans. Can J Cardiol 1991;7:117–124.
- Sunga P, Pritchard H, Rabkin SW: The effect of cyclic AMP on choline uptake and phosphatidylcholine biosynthesis in cultured chick heart cells. Biochem Cell Biol 1988;66:231–236.
- Szymanska G, Pikula S, Zborowski J: Effect of hyper- and hypothyroidism on phospholipid fatty acid composition and phospholipases activity in sarcolemma of rabbit cardiac muscle. Biochim Biophys Acta 1991;1083:265–270.
- Aussel C, Pelassy C: Effects of antiarrhythmic drugs on phospholipid metabolism in Jurkat T cells: the potassium channel blocker, clofilium, specifically increases phosphatidylserine synthesis. FEBS Lett 1992;304:281–284.
- Lyman EM, Dove JL, Sribney M: Effect of propylthiouracil-induced hypothyroidism on phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin synthesis in chick liver microsomes. Can J Biochem 1976;54:15–21.
- Simonides WS, van Hardeveld C: Effects of hypothyroidism on the distribution and fatty acyl composition of phospholipids in sarcoplasmic reticulum of fast skeletal muscle of the rat. Biochim Biophys Acta 1987;924:204–209.
- Zendzian-Piotrowska M, Gorska M, Dworakowski W, Gorski J: Effect of triiodothyronine on phospholipid metabolism in skeletal muscles of the rat. J Physiol Pharmacol 2000;51:103–110.
- Singh BN, Nademanee K: Amiodarone and thyroid function: clinical implications during antiarrhythmic therapy. Am Heart J 1983;106:857–869.
- Rabkin SW: Effect of antiarrhythmic drugs on choline uptake in cardiac cells in culture. Cardiovasc Res 1992;26:67–71.
- Cody V: Thyroid hormone interactions: molecular conformation, protein binding, and hormone action. Endocr Rev 1980;1:140–166.
- Kannan R, Pollak A, Singh BN: Elevation of serum lipids after chronic administration of amiodarone in rabbits. Atherosclerosis 1982;44:19–26.
- Kannan R, Kato R, Takikawa R, Huang TS, Chopra IJ, Singh BN: Lack of effect of 3,3′,5′-triiodothyronine (reverse T3) on cardiac function in the rabbit. Endocrine Res 1989;14:227–242.
- Saatov TS, Zainutdinov BR: Metabolism of phospholipids in various pathological states. Ukr Biochem J 1984;56:285–293.
- Vasdev SC, Korecky B, Rastogi RB, Singhal RL, Kako KJ: Myocardial lipid metabolism in cardiac hyper- and hypo-function: studies on triiodothyronine-treated and transplanted rat hearts. Can J Physiol Pharmacol 1977;55:1311–1319.
Article / Publication Details
Received: May 25, 2005
Accepted: August 01, 2005
Published online: February 22, 2006
Issue release date: February 2006
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 6
ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)
For additional information: https://www.karger.com/PHA
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
